# GANYMED Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ganymed-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Mainz, Germany
- Website: www.ganymed-pharmaceuticals.de
- Total disclosed funding: $129M
- Latest round: Series E (Nov 18, 2013)
- Investors on record: 13

## About

GANYMED Pharmaceuticals AG is engaged in the development and manufacturing of innovative pharmaceuticals targeted at treating various diseases, focusing on delivering effective solutions to diverse healthcare needs.GANYMED Pharmaceuticals AG, founded in 2001 in Mainz, Germany, specializes in pharmaceutical development. The company has undergone no major strategic pivots or changes in business operations and has not reported any subsidiaries. Christoph Huber, the founder of GANYMED, has been instrumental in its establishment. The company has completed a total of 9 deals, with its most recent deal on October 28, 2016, involving a TRADE SALE to Astellas Pharma Inc. for EUR 422.00 mn, marking the total amount raised to EUR 422.00 mn.GANYMED Pharmaceuticals focuses on developing a range of pharmaceuticals, including tablets, capsules, injections, creams, and syrups, aimed at treating a variety of health issues. Their products are distributed to hospitals, healthcare providers, and retail pharmacies, thereby ensuring patients have access to necessary treatments for chronic and acute conditions.In 2015, GANYMED Pharmaceuticals reported a revenue of EUR 246,703.40, while their EBITDA for 2016 was EUR -38,581,545.70, reflecting the financial dynamics of the company during that period.Following the TRADE SALE in October 2016 to Astellas Pharma, GANYMED Pharmaceuticals is poised for growth by focusing on the development of new pharmaceutical products and expanding into new geographic markets. Specific regions targeted for expansion have not been detailed, but the company aims to leverage recent funding to bolster its research and development initiatives, ensuring alignment with evolving healthcare demands.

## Funding rounds

- Series E, Nov 18, 2013, $60M — MIG Capital, ATS Beteiligungsverwaltung
- Series C, Apr 18, 2007, $45M — Landesbank Baden-Württemberg, First Capital, Nextech, Vi Partners, MIG Capital, Varuma, Ingro Finanz
- Series B, Jul 6, 2005, $15M — KfW Banking Group, Landesbank Baden-Württemberg, First Capital, Nextech, Vi Partners, VRP Rheinland
- Series A, Jun 1, 2002, $8.7M — First Capital, Nextech, Sud Beteiligungen, TBG Anesthesia Holdings, Inc., Vi Partners, Investitions- und Strukturbank Rheinland-Pfalz

## Investors

- First Capital (https://capitalatlas.ai/funds/first-capital) — Series A, Series B, Series C
- Nextech (https://capitalatlas.ai/funds/nextech) — Series A, Series B, Series C
- Sud Beteiligungen (https://capitalatlas.ai/funds/sud-beteiligungen) — Series A
- TBG Anesthesia Holdings, Inc. — Series A
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series A, Series B, Series C
- Investitions- und Strukturbank Rheinland-Pfalz (https://capitalatlas.ai/funds/investitions-und-strukturbank-rheinland-pfalz) — Series A
- KfW Banking Group — Series B
- Landesbank Baden-Württemberg — Series B, Series C
- VRP Rheinland — Series B
- MIG Capital (https://capitalatlas.ai/funds/mig-capital) — Series C, Series E
- Varuma — Series C
- Ingro Finanz — Series C
- ATS Beteiligungsverwaltung — Series E